Europe – GSK’s RSV vaccine candidate recommended by CHMP for older adults

There are currently no vaccines available to help protect older adults from RSV, a common contagious virus characterised by several mild, cold-like symptoms. Although...

Europe – European Health Union: Commission proposes pharmaceuticals reform for more accessible, affordable and...

Today, the Commission is proposing to revise the EU's pharmaceutical legislation - the largest reform in over 20 years - to make it more agile, flexible,...

UK – NICE approval for Janssen’s Darzalex combination

Recommendation concerns routine use across the NHS as therapy for multiple myeloma The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that the National...

UK – Kite’s CAR-T therapies recommended by NICE for certain blood cancers

The treatments, both given as one-off infusions, have been specifically recommended for use within the Cancer Drugs Fund (CDF), which pays for cancer treatments...

UK – Janssen and AbbVie’s Imbruvica combination recommended by NICE for leukaemia

CLL is the common type of leukaemia in adults, with around 3,800 people in the UK diagnosed with the disease each year. While patient outcomes...

Europe – Single-arm trials as pivotal evidence for the authorisation of medicines in the...

EMA has opened a public consultation on a  reflection paper that discusses key concepts for single-arm clinical trials that are submitted as pivotal evidence in support of marketing authorisation...

UK – AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

The anti-cancer medicine will now be routinely available for adults with HER2-negative, high-risk early breast cancer who have inherited faults in their BRCA1 or...

UK – Ipsen reacts to NICE’s Cabometyx verdict

Ipsen has expressed its disappointed regarding the National Institute for Health and Care Excellence’s (NICE) preliminary guidance which does not recommend Cabometyx – also...

Europe – New features further strengthen Priority Medicines scheme (PRIME)

EMA is introducing a number of new features to the PRIority Medicines (PRIME) scheme to strengthen its support for the development of medicines in areas of...

Europe – EU recommendations for 2023-2024 seasonal flu vaccine composition

EMA has issued the recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from...

NOS PROCHAINES FORMATIONS